標(biāo)題: Titlebook: Dyslipidemias in Kidney Disease; Adrian Covic,Mehmet Kanbay,Edgar V. Lerma Book 2014 Springer Science+Business Media New York 2014 Dialysi [打印本頁(yè)] 作者: Extraneous 時(shí)間: 2025-3-21 17:44
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease影響因子(影響力)
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease被引頻次
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease被引頻次學(xué)科排名
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease年度引用
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease年度引用學(xué)科排名
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease讀者反饋
書(shū)目名稱(chēng)Dyslipidemias in Kidney Disease讀者反饋學(xué)科排名
作者: Minutes 時(shí)間: 2025-3-21 23:34 作者: 急急忙忙 時(shí)間: 2025-3-22 00:55
d by leaders in the field.Includes supplementary material: .Dyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence. With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney d作者: refine 時(shí)間: 2025-3-22 05:52 作者: 接觸 時(shí)間: 2025-3-22 09:19
Book 2014lines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. .Dyslipidemias in Kidney Disease .captures the growing body of information on this subject matter. This book presents th作者: 斜坡 時(shí)間: 2025-3-22 15:10
degradation, and clearance. This chapter examines the lipid profile, underlying pathophysiological mechanism, and treatment of the dyslipidemia observed in patients with nephrotic syndrome, CKD, and diabetic nephropathy.作者: 斜坡 時(shí)間: 2025-3-22 19:38
https://doi.org/10.1007/978-1-4614-3903-5ts among elderly patients with kidney dysfunction seem to have a benefit, but the data remain limited. Moreover, it should always be considered that elderly patients with chronic kidney disease are at greater risk of adverse drug reactions; therefore, the lowest possible dose of medications should be used.作者: 女歌星 時(shí)間: 2025-3-22 23:13 作者: 北極人 時(shí)間: 2025-3-23 03:21 作者: arrhythmic 時(shí)間: 2025-3-23 06:12
Lipid Nephrotoxicity: New Concept for an Old Disease,distribution and renal vascular injury, and also causes statin resistance. This concept alters traditional understanding of the pathogenesis of lipid-mediated renal and vascular injury, and evaluation of renal and cardiovascular risk and lipid-lowering treatment in such patients.作者: ARIA 時(shí)間: 2025-3-23 11:07
Book 2014e latest clinical evidence and management guidance for patients of various demographics and stages of chronic kidney disease. Written for the nephrologist community, as well as cardiologists and general practitioners, this guide will provide practical knowledge and fill a much needed void in the literature..作者: braggadocio 時(shí)間: 2025-3-23 17:10
Environmental Resources Limitedn hemodialysis and peritoneal dialysis patients, and even in kidney transplant recipients. These abnormalities contribute to the risk of cardiovascular disease in these patients. Moreover, dyslipidemia may adversely affect the progression of renal disease in patients with CKD.作者: Hamper 時(shí)間: 2025-3-23 20:15 作者: 山頂可休息 時(shí)間: 2025-3-24 00:57
Hans Wu?ing,D. Goetz,I. Jahn,Hans Wu?ingrecommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.作者: 實(shí)施生效 時(shí)間: 2025-3-24 06:09
Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidnn hemodialysis and peritoneal dialysis patients, and even in kidney transplant recipients. These abnormalities contribute to the risk of cardiovascular disease in these patients. Moreover, dyslipidemia may adversely affect the progression of renal disease in patients with CKD.作者: heartburn 時(shí)間: 2025-3-24 07:08
Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease,chapter is to discuss the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs in patients with chronic kidney disease, those on dialysis, and patients following renal transplantation. This chapter will also discuss the safety, drug dosing, and drug interactions that are important in this group of patients.作者: dithiolethione 時(shí)間: 2025-3-24 14:43
Dyslipidemia in the Kidney Transplant Patient,recommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.作者: Temporal-Lobe 時(shí)間: 2025-3-24 18:35
https://doi.org/10.1007/978-1-4939-0515-7Dialysis; Dyslipidemias; Geriatric Patient; Hyperlipidemia; Kidney Disease; Lipid Metabolism; Lipid Nephro作者: Feckless 時(shí)間: 2025-3-24 21:48 作者: 堅(jiān)毅 時(shí)間: 2025-3-25 02:26
Adrian Covic,Mehmet Kanbay,Edgar V. LermaComprehensive resource that fills a significant knowledge gap.Features the latest clinical evidence and management guidance.Chapters authored by leaders in the field.Includes supplementary material: 作者: 法律的瑕疵 時(shí)間: 2025-3-25 04:25 作者: 槍支 時(shí)間: 2025-3-25 08:29 作者: 1分開(kāi) 時(shí)間: 2025-3-25 13:01
Gerd Plewig MD,Albert M. Kligman MD, PhDto the progression of both atherosclerosis and glomerulosclerosis. In this chapter, we discussed the promises of and exceptions to the original hypothesis and update the hypothesis by describing how inflammatory stress accompanying CKD fundamentally modifies cholesterol homeostasis, causing lipid re作者: 小卒 時(shí)間: 2025-3-25 18:22
Insulin Resistance Associated Acne,zed as an important cardiovascular risk factor in the general population, as well as in patients with chronic kidney disease (CKD). Several lines of evidence suggest that mechanisms and factors contributing to the pathogenesis of both cardiovascular and kidney injury may be similar. Moreover, abnorm作者: 額外的事 時(shí)間: 2025-3-25 21:30
Quantitative Measures of Sound,nts with chronic kidney disease (CKD) at all stages. Trial results from the general population may not be applicable to all patients with CKD because they have a different lipid profile with increased atherogenic lipid fractions. Lipid-lowering therapies in these patients may have substantial benefi作者: 凈禮 時(shí)間: 2025-3-26 01:34
Actin Regulation and Surface Catalysisar risk gradually increases with increasing stages of CKD, being the highest among patients with end-stage renal disease. Although the role of hyperlipidemia in the development of cardiovascular disease (CVD) in the general population has been efficiently documented, this relationship has been diffi作者: anarchist 時(shí)間: 2025-3-26 08:21 作者: Lobotomy 時(shí)間: 2025-3-26 10:39
https://doi.org/10.1007/978-3-662-05587-8 established treatment to reduce CV events, but the risk–benefit relationship of statins in patients with CKD has long been uncertain. A number of large-scale statin trials included significant numbers of patients with CKD stages 1–2, and the benefit in these patients with milder forms of CKD appear作者: 廢止 時(shí)間: 2025-3-26 13:43 作者: indigenous 時(shí)間: 2025-3-26 17:42 作者: Arrhythmia 時(shí)間: 2025-3-26 21:36
https://doi.org/10.1007/978-3-322-91381-4 abundance of novel risk factors unique to dialysis population. Dyslipidemia is related to increased CV risk in the general population. However, recent randomized trials showed no clear benefit of treating dyslipidemia in hemodialysis patients with a statin. Several hypotheses have been put forward 作者: resuscitation 時(shí)間: 2025-3-27 04:20
Hans Wu?ing,D. Goetz,I. Jahn,Hans Wu?inggnificant association between dyslipidemia and cardiovascular disease. Abnormalities include elevation of total cholesterol, triglyceride, and low-density lipoprotein fractions and are due to multiple factors, including immunosuppressant therapy, patient characteristics, and preexisting comorbiditie作者: persistence 時(shí)間: 2025-3-27 09:10
here are numerous factors that contribute to this health problem, including hypertension, disordered calcium homeostasis, and endothelial dysfunction. Dyslipidemia is another prominent feature of the CKD syndrome that potentiates the development of atherosclerosis and the risk of premature cardiovas作者: 虛弱 時(shí)間: 2025-3-27 10:36 作者: 半導(dǎo)體 時(shí)間: 2025-3-27 13:40
https://doi.org/10.1007/978-1-4614-3903-5s alternations in lipid metabolism that result in increased cardiovascular morbidity and mortality. As the incidence of kidney dysfunction increases with aging, understanding and treating abnormalities in lipid metabolism become central in the geriatric patients with chronic kidney disease. Unfortun作者: Ligneous 時(shí)間: 2025-3-27 20:08 作者: 糾纏 時(shí)間: 2025-3-28 01:54
rol in Adults (Adult Treatment Panel, ATP III), there has been a much progress and reduction in prevalence of high blood cholesterol in the United States. However, in ATP III, without excluding or including patients with chronic kidney disease (CKD), there are few specific recommendations for the ev作者: quiet-sleep 時(shí)間: 2025-3-28 05:34 作者: 貧困 時(shí)間: 2025-3-28 07:51 作者: Inferior 時(shí)間: 2025-3-28 10:37 作者: CRACY 時(shí)間: 2025-3-28 17:37
Actin Regulation and Surface Catalysisensity lipoprotein cholesterol are normal or low. To further complicate things, pathologic findings of arterial lesions in CKD consist of calcium-rich atherosclerotic plaques, whereas in classic atherosclerotic disease lipid-laden atheromatous or fibroatheromatous plaques are detected, implying a di作者: sleep-spindles 時(shí)間: 2025-3-28 21:42 作者: Cholecystokinin 時(shí)間: 2025-3-29 02:14 作者: Halfhearted 時(shí)間: 2025-3-29 05:33
https://doi.org/10.1007/978-3-322-91381-4compared with their HD counterparts. Modifications in some parameters of HD or PD along with pharmacologic therapy, mainly statins, constitute the current therapeutic armamentarium against dyslipidemia in dialysis patients. Future randomized controlled trials taking into account the particular chara作者: 河潭 時(shí)間: 2025-3-29 09:11
Phenomenology and Its Implications,ategories of pediatric patients are discussed in light of the limited number of studies in this population. Concerning the differences between the disease profile of adults and children, adult data could not be directly translated in children. Thus, prospective investigations regarding the clinical 作者: frivolous 時(shí)間: 2025-3-29 12:44 作者: tangle 時(shí)間: 2025-3-29 17:47 作者: 慢慢啃 時(shí)間: 2025-3-29 20:45 作者: 發(fā)怨言 時(shí)間: 2025-3-30 01:55
How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly,sis patients. Although fibrates can be used to treat mixed dyslipidemia, they need to be used carefully in patients with CKD, and limited available data suggest that fibrates may have a place in reducing cardiovascular risk in patients with mild to moderate CKD.作者: 流眼淚 時(shí)間: 2025-3-30 06:58
CVD in CKD: Focus on the Dyslipidemia Problem,ensity lipoprotein cholesterol are normal or low. To further complicate things, pathologic findings of arterial lesions in CKD consist of calcium-rich atherosclerotic plaques, whereas in classic atherosclerotic disease lipid-laden atheromatous or fibroatheromatous plaques are detected, implying a di作者: 積習(xí)難改 時(shí)間: 2025-3-30 11:05
The CKD Patient with Dyslipidemia,cation to small and dense low-density lipoproteins, which render the particles more atherogenic. These abnormalities contribute to the development of cardiovascular events, and they may worsen the progression of CKD..In this chapter we will briefly discuss the peculiar quantitative and qualitative a作者: Ledger 時(shí)間: 2025-3-30 14:27
Review of Clinical Trials Pertaining to Dyslipidemias in CKD, patients with a kidney transplant clearly benefit from statin therapy. In summary, available evidence clearly supports the use of statins in CKD patients not on dialysis and in those with a kidney transplant, in particular in the presence of concomitant CV risk factors or established CV disease.作者: 反抗者 時(shí)間: 2025-3-30 19:31
Dyslipidemia in Dialysis,compared with their HD counterparts. Modifications in some parameters of HD or PD along with pharmacologic therapy, mainly statins, constitute the current therapeutic armamentarium against dyslipidemia in dialysis patients. Future randomized controlled trials taking into account the particular chara作者: cushion 時(shí)間: 2025-3-30 23:51
Dyslipidemias in the Pediatric Chronic Kidney Disease Patient,ategories of pediatric patients are discussed in light of the limited number of studies in this population. Concerning the differences between the disease profile of adults and children, adult data could not be directly translated in children. Thus, prospective investigations regarding the clinical 作者: 脆弱吧 時(shí)間: 2025-3-31 02:14
Apheresis Methods in Hyperlipidemias,hese options had important morbidity attached to each other, selective low-density lipoprotein (LDL) apheresis has been considered as the most promising strategy in the treatment era. This chapter will focus on the techniques and outcomes of LDL-apheresis strategies on FH that could significantly im作者: aggrieve 時(shí)間: 2025-3-31 06:24
